NEW YORK, June 18 ― A repurposed arthritis drug has shown positive results in a clinical trial of patients hospitalised with Covid-19, according to a paper published Wednesday in theTofacitinib, taken orally and sold under the brand name Xeljanz among others, was tested in a trial of 289 patients hospitalised with severe Covid across 15 locations in Brazil.
After 28 days, 18.1 per cent of the group receiving the tofacitinib progressed to respiratory failure or death, compared to 29 per cent in the placebo group.Respiratory failure refers to a patient requiring noninvasive ventilation through an oxygen mask, or being intubated and placed on a mechanical ventilator.
Serious side effects occurred in 14.1 per cent in the tofacitinib group and in 12 per cent in the placebo group.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaymail - 🏆 1. / 86 Read more »